Treatment-related adverse events of antibody drug-conjugates in clinical trials

202513 citationsJournal Articlegold Open Access

Authors

Harold Nathan Tan

Marta Ascanio Morcillo · Royal Marsden Hospital

Juanita Lopez · Royal Marsden Hospital

Anna Minchom · Royal Marsden Hospital

Adam Sharp · Royal Marsden Hospital

Alec Paschalis · Institute of Cancer Research

Georgina Silva-Fortes · Royal Marsden Hospital

Abstract

Despite their design to minimize toxicity, ADCs were linked to significant AEs. Specific ADC components may contribute to distinct toxicities, necessitating more robust trial data to inform future ADC design.

Topics & Keywords

HER2/EGFR in Cancer Research Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Hematology & Oncology

Volume 18, Issue 1, pp. 71-71

DOI: 10.1186/s13045-025-01720-3

Field-Weighted Citation Impact: 14.20

Command Palette